A First-In-Human, Phase 1, Dose Escalation Study of SGR-3515 In Participants With Advanced Solid Tumors.
Latest Information Update: 01 Apr 2025
At a glance
- Drugs SGR 3515 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Schrodinger
Most Recent Events
- 23 Oct 2024 According to Schrodinger media release, the company expects initial data from this study in the second half of 2025.
- 30 Jul 2024 Status changed from not yet recruiting to recruiting.
- 12 Jun 2024 Status changed from planning to not yet recruiting.